Glycolic Acid Market to Reach USD 648.92 million by 2032
Austin, May 16, 2025 (GLOBE NEWSWIRE) -- The Glycolic Acid Market Size was valued at USD 349.07 million in 2024 and is expected to reach USD 648.92 million by 2032, growing at a CAGR of 8.06% over the forecast period of 2025-2032.Download PDF Sample of Glycolic Acid Market @ https://www.snsinsider.com/sample-request/7071
Widening Adoption of Active Ingredients Sparks Momentum in Global Glycolic-Based Skincare Innovations
The glycolic acid market is growing at a swift pace due to increasing demand in cosmetics, skin care, and dermatology. Technological advancements have increased their efficiency in acne and aging skin management, and widened their consumer base. Glycolic Acid-infused toiletries saw rising approvals in 2023 as reported by the U.S. FDA, as did domestic production on the part of the EPA. Major players, including The Chemours Company and BASF, declared strategic capacity expansions and product launches from 2022 to 2024, adding to supply. There is greater consumer knowledge of healthy skin and less-invasive procedures, especially in the U.S. and Europe. The consumer demand for natural formulations has further led to the transition to eco-friendly, sugarcane-derived Glycolic Acid. Combined, these trends point to the market's growth and the ingredient's growing presence in upcoming skincare and beauty projects.
The US Glycolic Acid Market Size was valued at USD 67.16 million in 2023, projected to reach USD 137.85 million by 2032, growing at a CAGR of 9.41% over the forecast period of 2024-2032.
The U.S. Glycolic Acid market is due to the growing consumer awareness regarding the skincare and dermatological benefits of the product. According to the American Academy of Dermatology, Glycolic Acid helps combat acne as well as aging, the same things skincare aspires to do, which is another reason demand is increasing. Nationally ranked U.S. players, such as Ashland and The Chemours Company, have increased production to meet demand, driven by continued growth in domestic consumption and advancements in cosmetic formulation.
Key Players:
The Chemours Company
CABB Group GmbH
China Petrochemical Corporation (Sinopec)
CrossChem Limited
Phibro Animal Health Corporation
Avid Organics Pvt. Ltd.
Mehul Dye Chem Industries
Zhonglan Industry Co., Ltd.
Shandong Xinhua Pharmaceutical Co., Ltd.
Saanvi Corp
Glycolic Acid Market Report Scope:
Report Attributes
Details
Market Size in 2024
USD 349.07 Million
Market Size by 2032
USD 648.92 Million
CAGR
CAGR of 8.06% From 2025 to 2032
Base Year
2024
Forecast Period
2025-2032
Historical Data
2021-2023
Report Scope & Coverage
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments
• By Grade (Cosmetic Grade, Technical Grade)• By Application (Personal Care & Dermatology, Industrial, Household, Others)
Key Drivers
• Surging Demand in Skincare and Personal Care Products Drives Market Growth.
Buy Full Research Report on Glycolic Acid Market 2025-2032 @ https://www.snsinsider.com/checkout/7071
Global Compliance Landscape Governing Safe Use of Glycolic Acid in Consumer Products
U.S. Food and Drug Administration has labelled Glycolic Acid as Generally Recognized As Safe (GRAS) when used in the typical cosmetic concentrations of 10% or less.
The use of Glycolic Acid in cosmetic products is allowed up to concentrations of 10% for rinse-off products, and up to 5% for leave-on products by the European Commission's SCCS.
In South Korea, glycolic acid is subject to use restrictions, which specify permissible concentration and labelling requirements for certain product types, including exfoliant and anti-aging products.
The Environmental Protection Agency (EPA) invokes under the Toxic Substances Control Act (TSCA) to control harm such as exposure and safe manufacturing to support the needs for testing and were to gain information.
Any product containing Glycolic Acid should also be subjected to dermatological and safety tests to be sold under REACH laws in the EU, so that your skin's well-being is protected.
By Grade, the Cosmetic Grade Segment Dominated the Glycolic Acid Market in 2024 with a 67% Market Share
This dominance is owed in no small part to the prevalent use of cosmetic-grade Glycolic Acid in skincare, for chemical peels, anti-ageing creams, and acne treatments. Cosmetic grade provides better purity and is required for sensitive skin areas. Large cosmetic companies such as Murad and Paula's Choice have expanded their lines of products with cosmetic-grade Glycolic Acid, resulting in higher demand from consumers. Moreover, the rising dermatological recommendations and FDA approvals for cosmetics further provide impetus to the market. The focus on safe and effective beauty ingredients in the U.S. and Europe also contributes to the growing interest in cosmetic-grade Glycolic Acid as compared to technical grade.
By Application, Personal Care & Dermatology Dominated the Glycolic Acid Market in 2024 with a 54% Market Share
Glycolic Acid demand in this segment is stimulated by increase in usage in the skin care routine for exfoliation, acne treatment, and anti-aging benefits. Brands such as Neutrogena and Olay introduced new Glycolic Acid products for various skin types making it more accessible. Growing consumer attention toward dermatological health and demand for minimally invasive cosmetic procedures are some other essential factors contributing to the market growth. Additionally, clinical research that demonstrates the effectiveness of Glycolic Acid in personal care has led to greater acceptance. Industrial and end-of-life applications are very critical as well, but rank below personal care owing to the very limited volume usage compared to personal care.
Asia Pacific dominated the Glycolic Acid Market in 2024, Holding a 39% Market Share
The domination of the region is attributed to the flourishing cosmetics and personal care industry in the region on back of growing disposable income, urbanization, beauty consciousness and changing consumer standards. Major skincare product demand has increased in countries including China, India and South Korea where Glycolic Acid types of skincare products are giving desired results. Factors to it leading the way in the global MRI systems market are the availability of prominent manufacturers and reduced cost of production in the region. Moreover, increase in R&D and product innovation investments in this region drive the market growth and adoption.
North America Emerged as the Fastest Growing Region in the Glycolic Acid Market with a Significant Growth Rate in The Forecast Period
Positive momentum is generated by strong consumer awareness, significant dermatological research, and stringent regulatory standards for product safety. In the U.S., the market is driven by the introduction of advanced Glycolic Acid delivery systems and formulations for sensitive skin. Prominent players, including Ashland and The Chemours Company, have increased their production and introduced new products in the region. Furthermore, rising consumer interest in non-invasive cosmetic procedures and science-based skincare products contributes to market growth. The robust healthcare infrastructure and higher disposable income in North America also favor this market growth.
If You Need Any Customization on Glycolic Acid Market Report, Inquire Now @ https://www.snsinsider.com/enquiry/7071
Recent Developments
March 2025: Brenntag partnered with PureTech to distribute formaldehyde-free Glycolic Acid solutions in North America, targeting clean beauty demand.
June 2023: Chemours sold its Glycolic Acid business to PureTech for $137 million to focus on core operations and strategic growth.Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Glycolic Acid Market Segmentation, By Grade
8. Glycolic Acid Market Segmentation, By Application
9. Regional Analysis
10. Company Profiles
11. Use Cases and Best Practice
12. Conclusion
Read Our Trending Reports:
Bioresorbable Polymers Market Analysis by 2032
Vanillic Acid Market Report Size 2024-2032
Benzoic Acid Market Growth & Future Trends (2024-2032)
Oxalic Acid Market - Global Research by 2032
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Canadian North Resources Inc. Reports Operational and Financial Results for the Second Quarter Ended June 30, 2025
Highlights: Expanded bio-metallurgical programs from initial bio-leaching tests indicating metal extraction of 97.86-98.5% nickel and 96.9-97.7% cobalt, with the goal of achieving similarly high recoveries of copper and PGE metals from the Ferguson Lake Ni-Cu-Co PGE Project located in southeast Nunavut, Canada. Continued evaluation of multiple metal processing technologies to produce market-ready battery-grade nickel and cobalt compounds, copper and PGE metals from a low-cost, low-carbon footprint mine. Working with local governments and indigenous communities for permissions, permits and licenses to conduct environmental baselines studies; communicating with investors, and potential partners to support the future development of the Ferguson Lake Project. TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Canadian North Resources Inc. ('Canadian North' or the 'Company') (TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) is pleased to report its operational and financial results for the second quarter ended June 30, 2025. Dr. Kaihui Yang, President and CEO of the Company, commented: 'In the second quarter, we have expanded the bio-leaching tests to develop a mineral processing flowsheet for the high recovery of nickel, cobalt, copper and PGE for the Ferguson Lake Project. The new tests are focused on the recovery of copper and PGE, in additional to nickel and cobalt, following up the exceptional results of the bio-leaching amenability tests completed in 2024, which indicate very high extraction rates for nickel (97.8-98.9%) and cobalt (96.0-97.7%) plus encouraging initial extractions of Cu of 73.6 -75.4%. The results of the new tests are pending. When proven, this flowsheet can simplify mineral processing, bypassing smelting and metal refining, and it will substantially reduce the capital expenditures needed for mine development, energy consumption, and operating cost for production. We believe that bio-leach extraction is a promising technology for developing a low-cost, low-carbon footprint mine at the Ferguson Lake Project.' 'We have actively communicated with the governmental agencies and local communities for the permissions, permits and licenses to conduct environmental baselines studies, and we have increased our communications with investors for the potential mine development of the Ferguson Lake Project.' Quarter 2 of 2025 Highlights: The Company also engaged in the following activities in the second quarter: During the second Quarter, the Company's team communicated with local governments and communities for the permissions, permits and licenses to start the environmental baseline studies at the Ferguson Lake Project. The Management has increased communications with shareholders, investors and potential strategic partners for the further development of the Company and its Ferguson Lake Project. On April 15, 2025, the Company filed its operational and financial results for the fiscal year 2024. During the year, it also publicly disclosed an updated NI 43-101 Mineral Resource Estimate for the Ferguson Lake Project, confirming it as one of the largest and highest-grade copper-nickel-cobalt-PGE deposits in North America. In addition, the Company initiated bio-leaching tests, which achieved 96–98% extraction rates for nickel and cobalt, supporting the potential use of this technology in developing a low-carbon, environmentally sustainable mining operation at Ferguson Lake. On April 16, 2025, the Company filed with the TSX Venture Exchange ('TSXV') an update on its Normal Course Issuer Bid ('NCIB') that was announced on April 5, 2024. During the past year (from April 5, 2024, to April 4, 2025), the Company has repurchased a total of 202,300 Common Shares at an average price of $0.98 per share under the NCIB. The completion of this repurchase underscores the Management's commitment to returning value to shareholders while optimizing the Company's capital structure. On April 24, 2025, the Company announced that it has filed with the TSX Venture Exchange ('TSXV') a Notice of Intention to Make a Normal Course Issuer Bid which is proposed to commence on April 28, 2025 and terminate on April 27, 2026 or the earlier of the date all shares which are subject to the Normal Course Issuer Bid are purchased. The Company believes that the current market price does not fully represent the intrinsic value of CNRI's Common Shares. On May 27, 2025, the Company filed the interim operational and financial results of the first Quarter, 2025. During the first Quarter, the Company continued evaluation of multiple metal processing technologies to produce market-ready battery-grade nickel and cobalt compounds, copper and PGE metals from a low-cost, low-carbon footprint mine for the Ferguson Lake Ni-Cu-Co-PGE Project. The Company commenced follow-up extensive bio-metallurgical programs from initial bio-leaching tests indicating metal extraction of 97.86-98.5% nickel and 96.9-97.7% cobalt, with the goal of achieving similarly high recoveries of copper and PGE metals. The Company enhanced engagement with local governments, Indigenous communities, investors, and potential partners to support the future development of the Ferguson Lake Project. In Quarter 2, 2025, the Company expanded the bioleaching tests with RPC for the high recovery of copper and PGE in addition to nickel and cobalt, and continued the flotation tests with SGS for the Ferguson Lake project. The technical team has also prepared for the field working programs upon receiving the permissions and permits from the governmental agencies. On June 21, 2025, the Company announced the voting results for the election of its Board of Directors at its Annual and Special Meeting of Shareholders held on June 19, 2025. For the quarter ended June 30, 2025, The Company ended the quarter with cash and cash equivalents of $143,233 and reported a net loss and comprehensive loss of $292,890 or $0.00 per share. For the quarter end Financial Statement and Management's Discussion and Analysis, please see the Company website at or on SEDAR. Qualified Person: Dr. Trevor Boyd, and Technical Advisor for Canadian North Resources, a qualified person as defined by Canadian National Instrument 43-101 standards, has reviewed the technical content of this news release and has approved its dissemination. About Canadian North Resources Inc. Canadian North Resources Inc. is an exploration and development company focusing on the critical metals for the clean-energy, electric vehicles, battery and high-tech industries. The company is advancing its 100% owned Ferguson Lake nickel, copper, cobalt, palladium, and platinum project in the Kivalliq Region of Nunavut, Canada. The Ferguson Lake mining property contains a substantial National Instrument 43-101 compliant Mineral Resource Estimate announced on March 19 2024, which include Indicated Mineral Resources of 66.1 million tonnes (Mt) containing 1,093 million pounds (Mlb) copper at 0.75%, 678Mlb nickel at 0.47%, 79.3Mlb cobalt at 0.05%, 2.34 million ounces (Moz) palladium at 1.10gpt and 0.419Moz platinum at 0.19gpt; and Inferred Mineral Resources of 25.9Mt containing 558Mlb copper at 0.98%, 333Mlb nickel at 0.58%, 39.6Mlb cobalt at 0.07%, 1.192Moz palladium at 1.43gpt and 0.205Moz platinum at 0.25gpt. In particular, 80% of the Indicated Mineral Resources is Open Pit with 52.7Mt at 0.65% copper, 0.43% nickel, 0.05% cobalt, 0.97gpt palladium and 0.17gpt platinum, which provides a solid Mineral Resource base for the initial development of a potential large mine. The Mineral Resource model indicates significant potential for resource expansion along strike and at depth over the 15 km long mineralized belt and a number of undefined mineralization zones and prospective areas. (Refer to 'Independent Technical Report on the Mineral Resource Estimate for the Ferguson Lake Project, Nunavut, Canada ('the Technical Report')', prepared by SRK Consulting and Ronacher McKenzie Geoscience Inc., effective March 19, 2024, filed by the Company to SEDAR at on May 3, 2024. The Technical Report has also been posted on the Company's website at Qualified Person: Dr. Trevor Boyd, and Technical Advisor for Canadian North Resources, a qualified person as defined by Canadian National Instrument 43-101 standards has reviewed the technical content of this news release and has approved its dissemination. Further information please visit the website at or contact: Dr. Kaihui Yang, President and CEOPhone: 905-696-8288 (Canada)1-888-688-8809 (Toll-Free)Email: info@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this news release, including statements which may contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'estimates', or similar expressions, and statements related to matters which are not historical facts, are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements, which reflect management's expectations regarding the Company's future growth, results of operations, performance, business prospects and opportunities, are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company believes that the expectations reflected in the forward-looking statements contained in this news release and the documents incorporated by reference herein are reasonable, but no assurance can be given that these expectations will prove to be correct. In addition, although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company undertakes no obligation to release publicly any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
First-in-human, Phase 1 Study of LRK-4189 to Begin in the Fourth Quarter CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the lipid kinase PIP4K2C for the treatment of microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors. The announcement was made at a presentation Larkspur was invited to give at the prestigious MEDI First Time Disclosures: Breakthroughs on New Medicines session at ACS Fall 2025, a meeting of the American Chemical Society in Washington, DC. Cancer cells maintain their fitness by developing survival adaptations that foster escape from intrinsic and extrinsic mechanisms of cell death in conditions of stress. Phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C) is a lipid kinase associated with poor outcomes in a range of cancers including CRC and breast cancers. PIP4K2C is co-opted by cancer cells to increase their fitness by evading immune surveillance and adapting to stress. 'Genetic studies have long highlighted PIP4K2C as a key player in cancer stress adaptation, but its extremely low kinase activity made it resistant to conventional inhibition approaches,' said Catherine Sabatos-Peyton, PhD, CEO of Larkspur Biosciences. 'With our novel degrader, LRK-4189, we've finally unlocked this critical pathway. By reducing cancer cell fitness, triggering intrinsic apoptosis, and engaging the immune system to clear residual tumor cells, LRK-4189 has the potential to overcome the limitations of earlier therapies. We're excited to advance this promising therapy to the clinic later this year.' According to the American Cancer Society, in the United States, approximately 150,000 cases of CRC are diagnosed annually, with MSS CRC accounting for about 85% of all CRC cases. About LRK-4189 LRK-4189 is an orally bioavailable, selective degrader of PIP4K2C with subnanomolar potency in primary human cells. LRK-4189-mediated degradation of PIP4K2C leads to intrinsic cancer cell death and activates interferon signaling, triggering multiple killing mechanisms in difficult-to-treat MSS CRC cells. In vivo, LRK-4189 demonstrates dose dependent PKPD with single agent efficacy in multiple models of CRC and synergy with first-line standard of care chemotherapy. In primary human CRC patient-derived spheroids, 50% of patient samples respond to LRK-4189 with a preferential response in MSS CRC, which compares favorably to benchmark cetuximab in the same platform (35%). Cetuximab may be either a first- or second-line treatment in people with RAS wild type CRC. LRK-4189 has completed IND-enabling studies and expects to initiate a Phase 1 clinical trial in Q4 2025. About Larkspur Biosciences Larkspur Biosciences is pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness. Larkspur develops therapies that decrease cancer cell fitness and sensitizes the cells to intrinsic and immune-driven mechanisms of killing. The company is advancing first-in-class programs that target the adaptations cancer cells use to proliferate, invade tissue, and escape the immune system. LarkX, the company's proprietary bioinformatics platform, couples machine learning with tumor genetics to discover cancer cell fitness pathways that originate in the tumor and enrich clinical strategies for potential responders to its therapies across multiple types of cancer. Larkspur's founders include Lewis C. Cantley, PhD, professor of medicine at Dana-Farber Cancer Institute, professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, PhD, professor of neurology at Harvard Medical School, senior scientist at Brigham and Women's Hospital; and Nathanael Gray, PhD, professor of chemical and systems biology at Stanford University. Visit us at and follow us on LinkedIn and X. Media Contact:Dan BoyleScientPRdan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Hepsiburada Submits Amendment to 6-K
ISTANBUL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, D-MARKET Elektronik Hizmetler ve Ticaret Anonim Şirketi (the 'Company') furnished to the Securities and Exchange Commission a Form 6-K (the 'Original Form 6-K') containing certain exhibits relating to the Company's Annual General Assembly Meeting of Shareholders for, and with respect to, the financial year 2024, to be held on September 15, 2025. This Amendment No. 1 to the Original Form 6-K amends the Original Form 6-K solely for the purpose of amending and restating Exhibit 99.4 (Board of Directors' Annual Report for 2024) in its entirety, due to an inadvertent clerical error contained in the version included in the Original Form 6-K. Except as described above, the Original Form 6-K remains unchanged. About Hepsiburada Hepsiburada is a leading e-commerce technology platform in Türkiye, operating through a hybrid model that combines first-party direct sales (1P) and a third-party marketplace (3P) with approximately 100 thousand its vision of leading the digitalization of commerce, Hepsiburada serves as a reliable, innovative and purpose-driven companion in consumers' daily lives. Hepsiburada's e-commerce platform offers a broad ecosystem of capabilities for merchants and consumers including last-mile delivery, fulfilment services, advertising solutions, cross-border sales, payment services and affordability solutions. Hepsiburada's integrated fintech platform, Hepsipay, provides secure payment solutions, including digital wallets, general-purpose loans, buy now pay later (BNPL) and one-click checkout, enhancing shopping convenience for consumers across online and offline while driving higher sales conversions for its founding in 2000, Hepsiburada has been purpose-driven, leveraging its digital capabilities to empower women in the Turkish economy. In 2017, Hepsiburada launched the 'Technology Empowerment for Women Entrepreneurs' program, which has supported approximately 65 thousand female entrepreneurs across Türkiye in reaching millions of customers. Investor Relations Contactir@ Media Contactcorporatecommunications@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
